
Stem Cell Therapy for COPD
7 min readMSC infusions have a real safety record in COPD trials, but the largest placebo-controlled study found no lung function benefit — with one intriguing signal in patients with high inflammation.
An independent reference library on stem cell therapy and cancer immunotherapy research.
471 articles · 2 topics · 351 Stem Cell Research · 120 Cancer Immunotherapy
Step 1 — Topic
Step 2 — Category
All 471 articles

MSC infusions have a real safety record in COPD trials, but the largest placebo-controlled study found no lung function benefit — with one intriguing signal in patients with high inflammation.

Sourcing, lab processing, delivery, monitoring and follow-up: a step-by-step walkthrough of what a stem cell infusion actually involves, from bone marrow aspiration to the DMSO garlic taste.

China's NMPA approved satri-cel for CLDN18.2-positive advanced gastric cancer — the first CAR T-cell therapy ever approved for a solid tumor, on randomized phase 2 data with modest gains and near-universal severe toxicity.

CRS affects the majority of CAR-T patients, but standardized ASTCT grading, FDA-approved tocilizumab and earlier intervention have made it a risk clinical teams now anticipate and manage.

Both redirect T cells against blood cancers, but CAR-T delivers deeper responses while off-the-shelf bispecifics start faster, cause less severe CRS and cost roughly $330,000 less over 12 months.

Small trials of iPSC and progenitor-cell therapy for spinal cord injury show encouraging multi-year safety and real motor recovery in some patients, but no stem cell treatment is FDA-approved for SCI.

Long-term data show stem cell augmentation can cut rotator cuff re-tear rates significantly, but the FDA has not approved these treatments for any orthopedic condition — here's what the evidence actually supports.

Twelve-month data on eight Parkinson's patients show a personalized, autologous iPSC-derived cell therapy was safe and linked to real symptom gains — early, promising, and not yet FDA-approved.

Potency determines what a stem cell can become — from totipotent cells that build an entire embryo to unipotent cells locked into one job — and why that hierarchy shapes both promise and risk in therapy.

CAR-T cures leukemia but remains unapproved for any solid tumor — here's the biology behind that gap, and the real trial data (gastric, neuroblastoma, glioblastoma) suggesting it may be closing.

A plain-language guide to regenerative medicine — what stem cells do, where they come from, which conditions are under study, and how regulators sort treatments by risk.

Stem cells rebuild tissue; immune cells defend it. The two are routinely conflated in clinic marketing, and the distinction changes what each can plausibly do.
Every feature article on regenmedreview carries a Sources block listing its references. Where the original source material included no external citations, that is stated explicitly rather than left blank.